534 related articles for article (PubMed ID: 25686005)
1. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
2. Marine natural products and other derivatives as potent indoleamine 2,3-dioxygenase inhibitors.
Delfourne E
Mini Rev Med Chem; 2012 Sep; 12(10):988-96. PubMed ID: 22512584
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).
Dolušić E; Frédérick R
Expert Opin Ther Pat; 2013 Oct; 23(10):1367-81. PubMed ID: 23992582
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
Yentz S; Smith D
BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
[TBL] [Abstract][Full Text] [Related]
5. Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties.
Serra S; Moineaux L; Vancraeynest C; Masereel B; Wouters J; Pochet L; Frédérick R
Eur J Med Chem; 2014 Jul; 82():96-105. PubMed ID: 24878638
[TBL] [Abstract][Full Text] [Related]
6. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
7. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Bakmiwewa SM; Fatokun AA; Tran A; Payne RJ; Hunt NH; Ball HJ
Bioorg Med Chem Lett; 2012 Dec; 22(24):7641-6. PubMed ID: 23122865
[TBL] [Abstract][Full Text] [Related]
8. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
9. Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.
Smith JR; Evans KJ; Wright A; Willows RD; Jamie JF; Griffith R
Bioorg Med Chem; 2012 Feb; 20(3):1354-63. PubMed ID: 22112538
[TBL] [Abstract][Full Text] [Related]
10. Heme-containing enzymes and inhibitors for tryptophan metabolism.
Yan D; Lin YW; Tan X
Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Lee DH; Lee JY; Jeong J; Kim M; Lee KW; Jang E; Ahn S; Lee CH; Hwang JY
Molecules; 2017 Nov; 22(11):. PubMed ID: 29120388
[TBL] [Abstract][Full Text] [Related]
12. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.
Lin SY; Yeh TK; Song JS; Hung MS; Cheng MF; Liao FY; Li AS; Cheng SY; Lin LM; Chiu CH; Wu MH; Lin YJ; Hsiao W; Sun M; Wang YH; Huang CH; Tang YC; Chang HH; Huang ZT; Chao YS; Shih C; Pan SL; Wu SY; Kuo CC; Ueng SH
Bioorg Chem; 2018 Apr; 77():600-607. PubMed ID: 29494816
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
Muller AJ; Malachowski WP; Prendergast GC
Expert Opin Ther Targets; 2005 Aug; 9(4):831-49. PubMed ID: 16083346
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.
Di Pucchio T; Danese S; De Cristofaro R; Rutella S
Expert Opin Ther Pat; 2010 Feb; 20(2):229-50. PubMed ID: 20100004
[TBL] [Abstract][Full Text] [Related]
16. Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.
Davar D; Bahary N
Target Oncol; 2018 Apr; 13(2):125-140. PubMed ID: 29302770
[TBL] [Abstract][Full Text] [Related]
17. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
Yang S; Li X; Hu F; Li Y; Yang Y; Yan J; Kuang C; Yang Q
J Med Chem; 2013 Nov; 56(21):8321-31. PubMed ID: 24099220
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase.
Reddy SV; Reddy KT; Kumari VV; Basha SH
J Biomol Struct Dyn; 2015; 33(12):2695-709. PubMed ID: 25671592
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors.
Huang Q; Zheng M; Yang S; Kuang C; Yu C; Yang Q
Eur J Med Chem; 2011 Nov; 46(11):5680-7. PubMed ID: 21925773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]